Compare Stocks → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison TSE:APS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPSAptose BiosciencesC$1.68+1.8%C$2.14C$1.65▼C$11.40C$26.39M1.448,857 shs4,820 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPSAptose Biosciences-2.94%-5.71%-21.05%-40.43%+150.00%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPSAptose BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPSAptose BiosciencesN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPSAptose BiosciencesN/AN/AC$1.05 per share1.60C$1.03 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPSAptose Biosciences-C$51.21M-C$10.49N/A∞N/AN/A-225.00%-102.23%5/13/2024 (Estimated)Latest OXB and APS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023APSAptose Biosciences-C$1.98-C$1.96+C$0.02-C$1.96N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPSAptose BiosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPSAptose Biosciences14.270.785.41OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPSAptose Biosciences9.80%Insider OwnershipCompanyInsider OwnershipAPSAptose Biosciences20.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPSAptose Biosciences3115.71 millionN/ANot OptionableOXB and APS HeadlinesSourceHeadlineAptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 28 at 5:43 PMAptose Biosciences's Earnings: A Previewbenzinga.com - March 25 at 1:49 PMAptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Optionfinance.yahoo.com - January 31 at 5:42 PMClosing Bell: Aptose Biosciences Inc flat on Wednesday (APS)theglobeandmail.com - December 20 at 8:06 PMAptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meetingfinance.yahoo.com - December 9 at 8:29 PMAptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Rolefinance.yahoo.com - November 30 at 5:41 PMAptose Biosciences Inc. (NASDAQ:APTO) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 10 at 12:53 PMAptose Reports Results for the Third Quarter 2023finance.yahoo.com - November 9 at 8:15 PMAptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meetingtheglobeandmail.com - November 2 at 12:30 PMAptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meetingfinance.yahoo.com - November 2 at 12:30 PMAptose Biosciences, Inc.: Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinibfinanznachrichten.de - October 30 at 1:16 PMAptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023finance.yahoo.com - October 26 at 8:12 AMPromising Prospects of Tuspetinib Drive Buy Rating for Aptose Biosciences: An Analyst’s Perspectivemarkets.businessinsider.com - October 20 at 8:50 AMClosing Bell: Aptose Biosciences Inc up on Friday (APS)theglobeandmail.com - October 7 at 8:23 AMClosing Bell: Aptose Biosciences Inc up on Thursday (APS)theglobeandmail.com - August 25 at 5:05 PMClosing Bell: Aptose Biosciences Inc flat on Monday (APS)theglobeandmail.com - August 22 at 9:24 AMAptose Biosciences, Inc.: Aptose Reports Results for the Second Quarter 2023finanznachrichten.de - August 11 at 6:19 AMAptose Reports Results for the Second Quarter 2023finance.yahoo.com - August 11 at 1:19 AMAptose Biosciences: Top 10 Undervalued Biotechnology Industry Stocks (APS)theglobeandmail.com - August 7 at 12:13 AMAptose Biosciences: Stocks Undervalued by Analyst Consensus on TSX (APS)theglobeandmail.com - July 21 at 11:31 PMAptose Biosciences, Inc.: Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliancefinanznachrichten.de - June 27 at 7:38 AMAptose Biosciences, Inc.: Aptose Biosciences Provides Update on Reverse Stock Splitfinanznachrichten.de - June 5 at 8:57 AMAptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023finance.yahoo.com - May 31 at 8:04 AMAptose to sell up to $25M stock in the U.S.seekingalpha.com - May 26 at 7:57 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAptose BiosciencesTSE:APSAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
